Ovaire01: Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France

Sponsor
Centre Leon Berard (Other)
Overall Status
Unknown status
CT.gov ID
NCT02981901
Collaborator
Cancer Côte d'or registry (Other), Cancer Calvados registry (Other)
376
3
35
125.3
3.6

Study Details

Study Description

Brief Summary

No structured organization for ovarian first line management emerges in France. Management across France seems to depend on regional contexts.

Regions display no specific organization or delineate regional network for the ovarian cancer management or report centralized management revolving around referent centers. These different templates present a major problem in identifying differences, costs and benefit.

To deal with this issue the Investigators propose a health economic evaluation based on cost-effectiveness analyses, completed with a budget impact analysis. This study will investigate the cost-effective management of patients with initial ovarian cancer using databases representative of different parts of French territories.

Condition or Disease Intervention/Treatment Phase
  • Other: Patient with ovarian epithelial cancer

Study Design

Study Type:
Observational
Actual Enrollment :
376 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France
Actual Study Start Date :
Jan 1, 2017
Anticipated Primary Completion Date :
Dec 1, 2019
Anticipated Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Patient with ovarian epithelial cancer

Ovarian epithelial cancer diagnosed in 2012

Other: Patient with ovarian epithelial cancer

Outcome Measures

Primary Outcome Measures

  1. Incremental cost-effectiveness ratio expressed in cost per relapse-free year gained [2 years after diagnosis]

    To perform a cost-effectiveness analysis in order to evaluate the most efficient organization for ovarian cancer in 1st line ot treatment

Secondary Outcome Measures

  1. Incremental cost-effectiveness ratio expressed in cost per QALY(Quality-Adjusted Life Year) gained. [2 years after diagnosis]

  2. Budget impact analysis [2 years after diagnosis]

    Cost assessment performed retrospectively for each patient: hospital stays, visits and other health-related costs will be identified and measured based on the French national Health Insurance perspective. QALY (Quality-Adjusted Life Year)

  3. Relapse-free survival (RFS) [RFS will be assessed 2 years after diagnosis]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Ovarian epithelial cancer initially diagnosed in 2012

  • Age > 18 years old

  • Residency in France (Rhône-Alpes region, District of Calvados and Cotes d'Or)

  • First-line ovarian epithelial cancer

Exclusion Criteria:
  • Relapsed ovarian epithelial cancer

  • Non epithelial ovarian cancer

Contacts and Locations

Locations

Site City State Country Postal Code
1 Calvados registry Caen France
2 Côte d'or registry Dijon France
3 Oveval Lyon France

Sponsors and Collaborators

  • Centre Leon Berard
  • Cancer Côte d'or registry
  • Cancer Calvados registry

Investigators

  • Principal Investigator: Isabelle RAY-COQUARD, PU-PH, Centre Leon Berard

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Leon Berard
ClinicalTrials.gov Identifier:
NCT02981901
Other Study ID Numbers:
  • Ovaire01
First Posted:
Dec 5, 2016
Last Update Posted:
Aug 23, 2018
Last Verified:
Aug 1, 2018
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2018